Regulated delayed expression of rfc enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines

Vaccine

Volumn 28, Issue 37, 2010, Pages 6094-6103

  Kong, Qingke ^a   Liu, Qing ^a   Jansen, Angela M ^a   Curtiss, Roy ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Arabinose regulated rfc expression; PspA

Indexed keywords

ARABINOSE; BACTERIAL PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN; PROTEIN RFC; TYPHOID VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; GLYCOSYLTRANSFERASE; HETEROPHILE ANTIGEN; IMMUNOGLOBULIN G; LIVE VACCINE; O-ANTIGEN POLYMERASE; PNEUMOCOCCAL SURFACE PROTEIN A; SALMONELLOSIS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM MUTANT; CODON; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PLASMID; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBOSOME; SALMONELLA ENTERICA; SALMONELLOSIS; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; PATHOGENICITY; PNEUMOCOCCAL INFECTIONS; PROMOTER REGION; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; VIRULENCE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, HETEROPHILE; ARABINOSE; BACTERIAL PROTEINS; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; HEXOSYLTRANSFERASES; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUTATION; PNEUMOCOCCAL INFECTIONS; PROMOTER REGIONS, GENETIC; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, ATTENUATED; VIRULENCE;

EID: 77955519403     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.074     Document Type: Article

References (50)

1. Cheminay C., Hensel M. Rational design of Salmonella recombinant vaccines. Int J Med Microbiol 2008, 298(January (1-2)):87-98.
2. Cardenas L., Clements J.D. Oral immunization using live attenuated Salmonella spp as carriers of foreign antigens. Clin Microbiol Rev 1992, 5(July (3)):328-342.
3. Curtiss R. Bacterial infectious disease control by vaccine development. J Clin Invest 2002, 110(October (8)):1061-1066.
4. Medina E., Guzman C.A. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001, 19(February (13-14)):1573-1580.
5. Bueno S.M., Gonzalez P.A., Kalergis A.M. Use of genetically modified bacteria to modulate adaptive immunity. Curr Gene Ther 2009, 9(June (3)):171-184.
6. Germanie R., Furer E. Immunity in experimental salmonellosis 2. basis for avirulence and protective capacity of galE mutants of Salmonella typhimurium. Infect Immun 1971, 4(6):663.
7. Stevenson G., Manning P.A. Galactose epimeraseless (GalE) mutant G30 of Salmonella typhimurium is a good potential live oral vaccine carrier for fimbrial antigens. FEMS Microbiol Lett 1985, 28(3):317-321.
8. Hone D.M., Attridge S.R., Forrest B., Morona R., Daniels D., Labrooy J.T., et al. A galE-via (Vi-antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun 1988, 56(May (5)):1326-1333.
9. Collins L.V., Hackett J. Sequence of the phosphomannose isomerase encoding gene of Salmonella typhimurium. Gene 1991, 103(July (1)):135-136.
10. Collins L.V., Attridge S., Hackett J. Mutations at rfc or pmi attenuate Salmonella typhimurium virulence for mice. Infect Immun 1991, 59(March (3)):1079-1085.
11. Li Y., Wang S., Scarpellini G., Gunn B., Xin W., Wanda S.Y., et al. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci USA 2009, 106(January (2)):593-598.
12. Curtiss R., Zhang X., Wanda S.Y., Kang HoYoung, Konjufca V., Li Y., et al. Induction of host immune responses using Salmonella-vectored vaccines. Virulence mechanisms of bacterial pathogens 2007, ASM Press, Washington, DC, pp. 297-313. 4th ed.
13. Hone D., Morona R., Attridge S., Hackett J. Contruction of defined galE mutants of Salmonella for use as vaccines. J Infect Dis 1987, 156(July (1)):167-174.
14. Nagy G., Danino V., Dobrindt U., Pallen M., Chaudhuri R., Emody L., et al. Down-regulation of key virulence factors makes the Salmonella enterica serovar Typhimurium rfaH mutant a promising live-attenuated vaccine candidate. Infect Immun 2006, 74(October (10)):5914-5925.
15. Artsimovitch I., Landick R. The transcriptional regulator RfaH stimulates RNA chain synthesis after recruitment to elongation complexes by the exposed nontemplate DNA strand. Cell 2002, 109(2):193-203.
16. Nagy G., Palkovics T., Otto A., Kusch H., Kocsis B., Dobrindt U., et al. "Gently rough": the vaccine potential of a Salmonella enterica regulatory lipopolysaccharide mutant. J Infect Dis 2008, 198(December (11)):1699-1706.
17. Whitfield C. Biosynthesis of lipopolysaccharide o-antigens. Trends Microbiol 1995, 3(May (5)):178-185.
18. Raetz C.R.H., Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002, 71:635-700.
19. Tran A.X., Whitfield C. Lipopolysaccharides (endotoxins). Encyclopedia of microbiology 2009, Academic Press, Oxford, pp. 513-28.
20. Curtiss R., Wanda S.-Y., Gunn B.M., Zhang X., Tinge S.A., Ananthnarayan V., et al. Salmonella enterica serovar Typhimurium strains with regulated delayed attenuation in vivo. Infect Immun 2009, 77(March (3)):1071-1082.
21. Kong Q., Liu Q., Roland K.L., Curtiss R. Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar Typhimurium vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen. Infect Immun 2009, 77(December (12)):5572-5582.
22. Bertani G. Studies on lysogenesis I.: the mode of phage liberation by lysogenic Escherichia coli. J Bacteriol 1951, 62(September (3)):293-300.
23. + expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain. Nat Bio-technol 1988, 6(June (6)):693-697.
24. Neidhardt F.C., Bloch P.L., Smith D.F. Culture medium for enterobacteria. J Bacteriol 1974, 119(September (3)):736-747.
25. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 2nd ed.
26. Hitchcock P.J., Brown T.M. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver stained polyacrylamide gels. J Bacteriol 1983, 154(1):269-277.
27. Schmieger H. Phage P22 mutants with increased or decreased transduction abilities. Mol Gen Genet 1972, 119(1):75-88.
28. Curtiss R.I. Chromosomal aberrations associated with mutations to bacteriophage resistance in Escherichia Coli. J Bacteriol 1965, 89(1):28.
29. Wiegand I., Hilpert K., Hancock R.E.W. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protocols 2008, 3(2):163-175.
30. Kang H.Y., Srinivasan J., Curtiss R.I. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar Typhimurium vaccine. Infect Immun 2002, 70(April (4)):1739-1749.
31. Xin W., Wanda S.Y., Li Y., Wang S., Mo H., Curtiss R. Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect Immun 2008, 76(July (7)):3241-3254.
32. Li Y., Wang S., Xin W., Scarpellini G., Shi Z., Gunn B., et al. A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Infect Immun 2008, 76(November (11)):5238-5246.
33. Nayak A.R., Tinge S.A., Tart R.C., McDaniel L.S., Briles D.E., Curtiss R. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun 1998, 66(August (8)):3744-3751.
34. Nevola J.J., Stocker B.A.D., Laux D.C., Cohen P.S. Colonization of the mouse intestine by an avirulent Salmonella typhimurium strain and its lipopolysaccharide-defective mutants. Infect Immun 1985, 50(1):152-159.
35. Kwon Y.M., Cox M.M., Calhoun L.N. Salmonella-based vaccines for infectious diseases. Expert Rev Vaccines 2007, 6(April (2)):147-152.
36. Stocker B.A.D., Makela P.H. Genetic determination of bacterial virulence, with special reference to Salmonella. Curr Top Microbiol Immunol 1986, 124:149-172.
37. Stocker B.A.D., Makela P.H. Genetics of (gram-negative) bacterial surface. Proc Roy Soc Lond B Biol 1978, 202(1146):5-30.
38. Nagy G., Pal T. Lipopolysaccharide: a tool and target in enterobacterial vaccine development. Biol Chem 2008, 389(May (5)):513-520.
39. Nagy G., Emody L., Pal T. Strategies for the development of vaccines conferring broad-spectrum protection. Int J Med Microbiol 2008, 298(July (5-6)):379-395.
40. Coynault C., Robbe-Saule V., Norel F. Virulence and vaccine potential of Salmonella typhimurium mutants deficient in the expression of the RpoS (sigma (S)) regulon. Mol Microbiol 1996, 22(October (1)):149-160.
41. Na H.S., Kim H.J., Lee H.C., Hong Y., Rhee J.H., Choy H.E. Immune response induced by Salmonella typhimurium defective in ppGpp synthesis. Vaccine 2006, 24(March (12)):2027-2034.
42. Briles D.E., Hollingshead S.K., King J., Swift A., Braun P.A., Park M.K., et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000, 182(December (6)):1694-1701.
43. McDaniel L.S., McDaniel D.O., Hollingshead S.K., Briles D.E. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect Immun 1998, 66(October (10)):4748-4754.
44. Voedisch S., Koenecke C., David S., Herbrand H., Forster R., Rhen M., et al. Mesenteric lymph nodes confine dendritic cell-mediated dissemination of Salmonella enterica serovar Typhimurium and limit systemic disease in mice. Infect Immun 2009, 77(August (8)):3170-3180.
45. Martinoli C., Chiavelli A., Rescigno M. Entry route of Salmonella typhimurium directs the type of induced immune response. Immunity 2007, 27(December (6)):975-984.
46. Hassan J.O., Curtiss R. Control of colonization by virulent Salmonella typhimurium by oral immunization of chickens with avirulent D cya D crp Salmonella typhimurium. Res Microbiol 1990, 141(September-October (7-8)):839-850.
47. Roland K., Curtiss R., Sizemore D. Construction and evaluation of a Δc ya Δ crp Salmonella typhimurium strain expressing avian pathogenic Escherichia coli O78 LPS as a vaccine to prevent airsacculitis in chickens. Avian Dis 1999, 43(July-September (3)):429-441.
48. Briles D.E., King J.D., Gray M.A., McDaniel L.S., Swiatlo E., Benton K.A. PspA a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in mice. Vaccine 1996, 14(June (9)):858-867.
49. Edwards R.A., Keller L.H., Schifferli D.M. Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. Gene 1998, 207(January (2)):149-157.
50. Sun W., Wang S., Curtiss R. Highly efficient method for introducing successive multiple scarless gene deletions and markerless gene insertions into the Yersinia pestis chromosome. Appl Environ Microbiol 2008, 74(July (13)):4241-4245.